Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung

S D Robinson; C Lai; G Hotton; G Anand

Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung

Acute Med. 2019;18(3):197-199.

Authors

S D Robinson¹, C Lai¹, G Hotton², G Anand¹

Affiliations

¹ Department of Oncology, North Middlesex University Hospital, London.
² Department of Neurology, North Middlesex University Hospital, London.

PMID: 31536059

Abstract

The advent of immunotherapy in oncology has led to the emergence of a new spectrum of adverse effects. A number of these have the potential to contribute to life-threatening outcomes; and therefore require prompt identification and aggressive treatment to optimise management. In this report, we describe a case of pembrolizumab-induced CTCAE (common toxicity criteria for adverse events) grade 4 myositis in a non-small cell lung cancer patient.

Publication types

Case Reports

MeSH terms

Adenocarcinoma of Lung* / drug therapy
Antibodies, Monoclonal, Humanized* / adverse effects
Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Agents, Immunological* / adverse effects
Antineoplastic Agents, Immunological* / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Drug-Related Side Effects and Adverse Reactions
Humans
Lung Neoplasms* / drug therapy
Myositis* / chemically induced

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab